Richard Melde
Family Medicine · Phoenix, AZNPI 1710027438
Payments from drug & device makers
Across 95 payments — averaging $15.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Johnson & Johnson$241
- AstraZeneca$222
- AbbVie$210
- Pfizer$161
- Novo Nordisk$113
- Novartis$103
- plus $431 from 12 others
What the payments were for
- Food & beverage$1,481100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Johnson & Johnson | 13 | $241 |
| AstraZeneca | 16 | $222 |
| AbbVie(2 entities) | 18 | $210 |
| Pfizer | 9 | $161 |
| Novo Nordisk | 6 | $113 |
| Novartis | 5 | $103 |
| Boehringer Ingelheim | 6 | $100 |
| Amgen | 3 | $54 |
| GSK | 4 | $54 |
| Lilly USA, LLC | 3 | $49 |
| Merck | 3 | $45 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $33 |
| UCB, Inc. | 1 | $23 |
| Medtronic | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Grifols USA, LLC | 1 | $15 |
| Electromed, Inc. | 2 | $14 |
| Itamar Medical Inc | 1 | $12 |
How this compares
$1,481 in reported general payments places this provider in the 75th percentile of 2,099 family medicine providers in Arizona.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 73 | $99,043 |
| OzempicSemaglutide | 38 | $57,393 |
| JardianceEmpagliflozin | 30 | $42,333 |
| FarxigaDapagliflozin Propanediol | 28 | $39,711 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 33 | $30,808 |
| MounjaroTirzepatide | 20 | $25,011 |
| JanuviaSitagliptin Phosphate | 12 | $20,199 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 17 | $11,114 |
| Levothyroxine Sodium | 459 | $5,078 |
| Fentanyl | 12 | $4,073 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 24 | $3,400 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 94 | $3,124 |
| Omeprazole | 147 | $2,717 |
| Atorvastatin Calcium | 296 | $2,658 |
| Lisinopril | 297 | $2,069 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $161 | $99,04373 claims |
| Novo NordiskOzempic | $113 | $57,39338 claims |
| AstraZenecaFarxiga, Breztri Aerosphere | $222 | $50,82545 claims |
| Boehringer IngelheimJardiance | $100 | $42,33330 claims |
| GSKTrelegy Ellipta | $54 | $30,80833 claims |
| Lilly USA, LLCMounjaro | $49 | $25,01120 claims |
| MerckJanuvia | $45 | $20,19912 claims |
| AbbVieSynthroid | $210 | $2,03132 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,099 family medicine providers in Arizona.
Other family medicine in Phoenix
- Brock MerrittPhoenix$8.4M
- Douglas CunninghamPhoenix$4.9M
- Jeffrey ZacherPhoenix$2M
- Trisha TavaresPhoenix$1.6M
- David FrancykPhoenix$1.3M
- James BeachPhoenix$1.2M
- Peter LevinsPhoenix$971K
- Elysa ShawPhoenix$774K
- Mitchell EdelsteinPhoenix$741K
- Brian DedinskyPhoenix$589K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.